Hubei Goto BiopharmLtd Past Earnings Performance
Past criteria checks 0/6
Hubei Goto BiopharmLtd's earnings have been declining at an average annual rate of -38.9%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 2% per year.
Key information
-38.9%
Earnings growth rate
-45.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 2.0% |
| Return on equity | -1.6% |
| Net Margin | -2.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Shares Fly 42% But Investors Aren't Buying For Growth
Oct 09
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%
May 12Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear
May 02Lacklustre Performance Is Driving Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Low P/S
Feb 28Revenue & Expenses Breakdown
How Hubei Goto BiopharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 547 | -14 | 62 | 40 |
| 30 Jun 24 | 532 | 0 | 61 | 37 |
| 31 Mar 24 | 569 | 23 | 56 | 37 |
| 31 Dec 23 | 566 | 23 | 55 | 38 |
| 30 Sep 23 | 543 | 23 | 54 | 46 |
| 30 Jun 23 | 604 | 31 | 50 | 49 |
| 31 Mar 23 | 604 | 31 | 49 | 47 |
| 01 Jan 23 | 605 | 40 | 47 | 45 |
| 30 Sep 22 | 592 | 64 | 39 | 42 |
| 30 Jun 22 | 557 | 64 | 41 | 41 |
| 31 Mar 22 | 570 | 76 | 41 | 39 |
| 01 Jan 22 | 591 | 78 | 41 | 37 |
| 30 Sep 21 | 595 | 76 | 36 | 35 |
| 30 Jun 21 | 569 | 76 | 29 | 28 |
| 31 Mar 21 | 573 | 71 | 27 | 26 |
| 31 Dec 20 | 468 | 53 | 21 | 22 |
| 31 Dec 19 | 465 | 73 | 23 | 26 |
| 31 Dec 18 | 437 | 71 | 17 | 27 |
| 31 Dec 17 | 334 | 47 | 19 | 23 |
Quality Earnings: 300966 is currently unprofitable.
Growing Profit Margin: 300966 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300966 is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare 300966's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 300966 has a negative Return on Equity (-1.61%), as it is currently unprofitable.